Fairfax Financial Holdings’s Trillium Therapeutics Inc. TRIL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-341,000
Closed -$5.99M 69
2021
Q3
$5.99M Buy
+341,000
New +$3.98M 0.2% 21

Other funds holding TRIL

Fairfax Financial Holdings's TRIL Position: Q4 2021 in Review

Fairfax Financial Holdings sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 341,000 shares — an estimated $5.99M sold.

Fairfax Financial Holdings first reported a position in TRIL in Q3 2021 and held it in 1 quarter. The position peaked at $5.99M in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

  • Fairfax Financial Holdings reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
  • Fairfax Financial Holdings sold 341,000 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $5.99M.
  • Fairfax Financial Holdings first reported a position in Trillium Therapeutics Inc. in Q3 2021 and held it in 1 quarter.
  • Fairfax Financial Holdings's Trillium Therapeutics Inc. position peaked at $5.99M in Q3 2021.
  • 2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Fairfax Financial Holdings's 13F filing for Q4 2021, filed 14 Feb 2022.